the aid library

LIST OPTIONS

Filter

10453

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (172)

View PDF (189)

Risk communication and community engagement for COVID-19 contact tracing: interim guidance

World Health Organization WHO (2021) C_WHO

Contact tracing is a key element of WHO’s recommended approach to control the spread of COVID-19 by breaking the chains of human-to-human transmission. This document provides guidance to health authorities at all levels to improve the success rate of contact tracing by informing efforts with RCCE... more

Download (407)

View PDF (423)

8 Ways to Prevent Breast Cancer

Siteman Cancer Center Locations (2021) C1

Breast cancer. Just reading those words can make many women worry. And that’s natural. Nearly everyone knows someone touched by the disease. But there is a lot of good news about breast cancer these days. Treatments keep getting better, and we know more than ever about ways to prevent the disease... more

Download (103)

View PDF (95)

Symptom-based screening tool for asthma syndrome among young children in Uganda

Nantanda, R.; Siersma, V.; Ndeezi, G. et al. npj Primary Care Respiratory Medicine (2020) CC

Under-diagnosis of asthma in ‘under-fives’ may be alleviated by improved inquiry into disease history. We assessed a questionnaire-based screening tool for asthma among 614 ‘under-fives’ with severe respiratory illness in Uganda. The questionnaire responses were compared to post hoc consensu... more

External Link

WHO Monographs On Selected Medicinal Plants - Volume 2

World Health Organization WHO (2007) C_WHO

• provide scientific information on the safety, efficacy, and quality control/ quality assurance of widely used medicinal plants, in order to facilitate their appropriate use in Member States; • provide models to assist Member States in developing their own mono- graphs or formularies for these... more

External Link

Air pollution and diabetes: it's time to get active!

O'Donovan, G.; Cadena-Gaitán, C. (2018) CC

Cardiovascular disease, diabetes, chronic obstructive pulmonary disease, cancers, and other non-communicable diseases are among the leading causes of morbidity and mortality in low-income, middle-income, and high-income countries, and The Lancet Taskforce recently made the case for investing in non-... more

Download (1590)

View PDF (1640)

The Oxfam Ebola Response in Liberia and Sierra Leone: An evaluation report for the Disasters Emergency Committee

Adams, J.; Llyod, A.; Miller, C. Oxfam (2015)

The context of the Ebola epidemic presented extreme challenges for Oxfam, as it did for many organisations. At the onset of the epidemic, there was a general lack of understanding of the disease and how to respond to it effectively and safely. A pervasive and persistent climate of fear, coupled with... more

Download (225)

View PDF (252)

Connecting Global Priorities: Biodiversity and Human Health

World Health Organization WHO (2015) C_WHO

Healthy communities rely on well-functioning ecosystems. They provide clean air, fresh water, medicines and food security. They also limit disease and stabilize the climate. But biodiversity loss is happening at unprecedented rates, impacting human health worldwide, according to a new state of knowl... more

Download (580)

View PDF (1937)

Guideline ‒ Alternative mass drug administration regimens to eliminate lymphatic filariasis
recommended

World Health Organization WHO (2017) C_WHO

Lymphatic filariasis is a vector-borne neglected tropical disease that causes damage of the lymphatic system and can lead to lymphoedema (elephantiasis) and hydrocele in infected individuals. The global baseline estimate of persons affected by lymphatic filariasis is 25 million men with hydrocele an... more

External Link

Knowledge, attitudes and practices about human African trypanosomiasis and their implications in designing intervention strategies for Yei county, South Sudan

Bukachi, SA.; Mumbo, AA.; Alak, ACD.; Sebit, W.; Rumunu, J. et al. PLOS Neclected Tropical Diseases (2018) CC

A clear understanding of the knowledge, attitudes and practices (KAP) of a particular community is necessary in order to improve control of human African trypanosomiasis (HAT).New screening and diagnostic tools and strategies were introduced into South Sudan, as part of integrated delivery of primar... more

External Link

World Heart Federation Cholesterol Roadmap 2022

Ray, K.K.; Ference, B.A.; Séverin, T. et al. World Heart Federation (2022) CC

Background: Atherosclerotic cardiovascular diseases (ASCVD) including myocardial infarction, stroke and peripheral arterial disease continue to be major causes of premature death, disability and healthcare expenditure globally. Preventing the accumulation of cholesterol-containing atherogenic lipopr... more

External Link

WHF Roadmap for Digital Health in Cardiology

Tromp, J.; Jindal, D.; Redfern, J. et al. Global Heart (2022) CC

ABSTRACT More than 500 million people worldwide live with cardiovascular disease (CVD). Health systems today face fundamental challenges in delivering optimal care due to ageing populations, healthcare workforce constraints, financing, availability and affordability of CVD medicine, and service del... more

Download (233)

View PDF (306)

Handbook for Integrated Vector Management in the Americas

Pan American Health Organization PAHO ; World Health Organization WHO (2019) C_WHO

This document compiles the recommendations made by the World Health Organization (WHO) and the Pan American Health Organization (PAHO) to help professionals in charge of vector control programs in Latin America and the Caribbean at the national, subnational, and local level update their knowledge in... more

Download (647)

View PDF (1379)

Integrating palliative care and symptom relief into primary health care : WHO guide for planners, implementers and managers

World Health Organization WHO (2018) C_WHO

Inequality of access to palliative care and symptom relief is one of the greatest disparities in global health care (1). Currently, there is avoidable suffering on a massive scale due to lack of access to palliative care and symptom relief in low- and middle-income countries (LMICs) (1). Yet basic p... more

Download (242)

View PDF (297)

Zimbabwe multi-sectoral cholera elimination plan 2018-2028

World Health Organization WHO; Regional Office for Africa; Cholera Secretariat Zimbabwe (2019) C_WHO

The Zimbabwe Multi-Sectoral Cholera Elimination Plan (2018–2028) aims to eradicate cholera by improving water, sanitation, and healthcare infrastructure, strengthening disease surveillance, and expanding oral cholera vaccination (OCV). The strategy focuses on five pillars, including public health ... more

Download (207)

View PDF (240)

Managing epidemics: key facts about major deadly diseases

World Health Organization (WHO) (2018) C_WHO

Epidemics of infectious diseases are occurring more often, and spreading faster and further than ever, in many different regions of the world. The background factors of this threat are biological, environmental and lifestyle changes, among others. A potentially fatal combination of newly-discovered ... more

Download (167)

View PDF (185)

Global alcohol action plan: Second draft, unedited

World Health Organization WHO (2021) C_WHO

The harmful use of alcohol causes approximately 3 million deaths every year and the overall burden of disease and injuries attributable to alcohol consumption remains unacceptably high. The pace of development and implementation of alcohol policies has been uneven in WHO regions, and resources and c... more

Download (442)

View PDF (592)

A toolkit for integrated vector management in sub-Saharan Africa

World Health Organization (WHO) (2016) C_WHO

This toolkit for integrated vector management (IVM) is designed to help national and regional programme managers coordinate across sectors to design and run large IVM programmes.
The toolkit provides the technical detail required to plan, implement, monitor and evaluate an IVM approach. IVM can... more

Download (131)

View PDF (149)

Draft Proposed programme budget 2022–2023: Building forward better

World Health Organization (WHO) World Health Organization (WHO) (2021) CC

The development of this draft Proposed programme budget 2022–2023 comes at a unique moment for WHO. The world is in the grip of the coronavirus disease (COVID-19) pandemic and faces health, social and economic consequences on an unprecedented scale. Although it is not known when the COVID-19 pande... more

Download (161)

View PDF (197)

Situational Brief: Newly Arrived Migrants & Asylum Seekers in Italy during the Covid-19 pandemic

Emelurumonye I. N., A. Miglietta Lancet Migration (2020) CC

On 30thJanuary 2020 the World Health Organization (WHO) declared the outbreak of coronavirus disease 2019 (COVID-19) in the People’s Republic of China to be a Public Health Emergency of International Concern (PHEIC) under the international Health Regulations. The following day, the Italian Governm... more

Guideline ‒ Alternative mass drug administration regimens to eliminate lymphatic filariasis recommended

Guideline ‒ Alternative mass drug administration regimens to eliminate lymphatic filariasis
recommended